Last reviewed · How we verify
Adaptol (mebicar)
Adaptol (generic name: mebicar) is a drug. It is currently in unknown development for Anxiety, Attention deficit hyperactivity disorder.
Adaptol is thought to work by modulating neurotransmitter activity in the brain.
Adaptol, also known as mebicar, is a small molecule drug with unknown drug class and target. It is used to treat anxiety and attention deficit hyperactivity disorder (ADHD). The commercial status of Adaptol is unclear, and it may be patented or have generic manufacturers. Key safety considerations are not well-documented. Further research is needed to fully understand its pharmacology and clinical use.
At a glance
| Generic name | mebicar |
|---|---|
| Therapeutic area | Neuroscience |
| Phase | unknown |
Mechanism of action
Imagine your brain is a busy city with many different streets and intersections. Adaptol helps to calm down the traffic by adjusting the flow of chemical messengers, or neurotransmitters, that carry signals between different parts of the brain. This can help to reduce anxiety and improve focus.
Approved indications
- Anxiety
- Attention deficit hyperactivity disorder
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adaptol CI brief — competitive landscape report
- Adaptol updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Adaptol
What is Adaptol?
How does Adaptol work?
What is Adaptol used for?
What is the generic name of Adaptol?
What development phase is Adaptol in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Anxiety
- Indication: Drugs for Attention deficit hyperactivity disorder
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing